Blueprint Medicines (BPMC) Competitors $129.46 0.00 (0.00%) As of 07/18/2025 Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BPMC vs. ONC, BNTX, SMMT, INSM, TEVA, GMAB, MRNA, RDY, QGEN, and VTRSShould you be buying Blueprint Medicines stock or one of its competitors? The main competitors of Blueprint Medicines include BeOne Medicines (ONC), BioNTech (BNTX), Summit Therapeutics (SMMT), Insmed (INSM), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), Moderna (MRNA), Dr. Reddy's Laboratories (RDY), Qiagen (QGEN), and Viatris (VTRS). These companies are all part of the "pharmaceutical products" industry. Blueprint Medicines vs. Its Competitors BeOne Medicines BioNTech Summit Therapeutics Insmed Teva Pharmaceutical Industries Genmab A/S Moderna Dr. Reddy's Laboratories Qiagen Viatris Blueprint Medicines (NASDAQ:BPMC) and BeOne Medicines (NASDAQ:ONC) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, institutional ownership, risk, analyst recommendations, media sentiment and profitability. Is BPMC or ONC more profitable? BeOne Medicines has a net margin of -3.89% compared to Blueprint Medicines' net margin of -27.70%. BeOne Medicines' return on equity of -1.25% beat Blueprint Medicines' return on equity.Company Net Margins Return on Equity Return on Assets Blueprint Medicines-27.70% -64.60% -17.22% BeOne Medicines -3.89%-1.25%-0.73% Does the media prefer BPMC or ONC? In the previous week, BeOne Medicines had 17 more articles in the media than Blueprint Medicines. MarketBeat recorded 17 mentions for BeOne Medicines and 0 mentions for Blueprint Medicines. BeOne Medicines' average media sentiment score of 0.43 beat Blueprint Medicines' score of 0.00 indicating that BeOne Medicines is being referred to more favorably in the news media. Company Overall Sentiment Blueprint Medicines Neutral BeOne Medicines Neutral Do analysts prefer BPMC or ONC? Blueprint Medicines currently has a consensus target price of $130.00, suggesting a potential upside of 0.42%. BeOne Medicines has a consensus target price of $330.89, suggesting a potential upside of 10.93%. Given BeOne Medicines' stronger consensus rating and higher possible upside, analysts clearly believe BeOne Medicines is more favorable than Blueprint Medicines.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Blueprint Medicines 0 Sell rating(s) 16 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.11BeOne Medicines 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility & risk, BPMC or ONC? Blueprint Medicines has a beta of 0.89, suggesting that its stock price is 11% less volatile than the S&P 500. Comparatively, BeOne Medicines has a beta of 0.27, suggesting that its stock price is 73% less volatile than the S&P 500. Which has stronger valuation & earnings, BPMC or ONC? Blueprint Medicines has higher earnings, but lower revenue than BeOne Medicines. BeOne Medicines is trading at a lower price-to-earnings ratio than Blueprint Medicines, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBlueprint Medicines$562.12M14.87-$67.09M-$2.47-52.41BeOne Medicines$3.81B8.58-$644.79M-$1.73-172.42 Do insiders & institutionals hold more shares of BPMC or ONC? 48.6% of BeOne Medicines shares are held by institutional investors. 4.2% of Blueprint Medicines shares are held by company insiders. Comparatively, 6.6% of BeOne Medicines shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. SummaryBeOne Medicines beats Blueprint Medicines on 12 of the 16 factors compared between the two stocks. Get Blueprint Medicines News Delivered to You Automatically Sign up to receive the latest news and ratings for BPMC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BPMC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BPMC vs. The Competition Export to ExcelMetricBlueprint MedicinesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.36B$2.98B$5.48B$9.57BDividend YieldN/A2.47%4.00%4.18%P/E Ratio-52.4117.9729.8825.14Price / Sales14.87293.78440.45103.02Price / CashN/A41.8335.9458.58Price / Book27.547.238.105.59Net Income-$67.09M-$54.43M$3.26B$265.48M7 Day PerformanceN/A0.22%0.65%1.22%1 Month Performance0.83%5.59%2.44%0.39%1 Year Performance41.58%9.98%27.59%23.47% Blueprint Medicines Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BPMCBlueprint Medicines0.693 of 5 stars$129.46flat$130.00+0.4%N/A$8.36B$562.12M-52.41640ONCBeOne Medicines1.3153 of 5 stars$294.51+1.0%$327.56+11.2%N/A$32.28B$3.81B-79.1711,000Trending NewsEarnings ReportAnalyst ForecastInsider TradeBNTXBioNTech1.9708 of 5 stars$112.79-2.2%$136.58+21.1%+40.5%$27.11B$2.98B-33.176,772Earnings ReportAnalyst ForecastSMMTSummit Therapeutics2.0573 of 5 stars$27.45-4.3%$34.67+26.3%+198.6%$20.39B$700K-80.73110Positive NewsOptions VolumeINSMInsmed3.6473 of 5 stars$101.75-2.1%$109.20+7.3%+54.0%$19.30B$363.71M-17.101,271Earnings ReportGap DownTEVATeva Pharmaceutical Industries2.9306 of 5 stars$16.53-0.1%$24.71+49.5%-2.8%$18.96B$16.62B-14.3736,830Insider TradeGMABGenmab A/S3.6707 of 5 stars$23.09-1.3%$37.80+63.7%-14.2%$14.81B$3.12B13.122,682News CoverageEarnings ReportShort Interest ↑MRNAModerna4.3279 of 5 stars$33.91-0.7%$46.11+36.0%-67.4%$13.11B$3.24B-3.885,800Trending NewsEarnings ReportAnalyst RevisionRDYDr. Reddy's Laboratories2.3325 of 5 stars$14.71+0.2%$16.95+15.3%-17.7%$12.28B$3.81B22.2827,811QGENQiagen3.5371 of 5 stars$51.00-1.5%$49.40-3.1%+11.8%$11.51B$2.00B127.875,765News CoverageEarnings ReportAnalyst ForecastVTRSViatris2.6692 of 5 stars$9.26-1.6%$10.40+12.3%-17.3%$10.87B$14.74B-2.9232,000Trending NewsEarnings ReportDividend AnnouncementShort Interest ↑Gap Up Related Companies and Tools Related Companies ONC Competitors BNTX Competitors SMMT Competitors INSM Competitors TEVA Competitors GMAB Competitors MRNA Competitors RDY Competitors QGEN Competitors VTRS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BPMC) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredSell this, buy thatWhat you don’t own matters just as much as what you do. That’s the thinking behind Eric Fry’s long-time strate...InvestorPlace | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Blueprint Medicines Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Blueprint Medicines With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
